News Release

BUSM researchers uncover cellular mechanism responsible for chronic inflammation, Type 2 diabetes

Peer-Reviewed Publication

Boston University School of Medicine

(Boston) – Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

Barbara Nikolajczyk, PhD, an associate professor of microbiology and medicine at BUSM, is the senior author of the study, which is currently featured in an online edition of the Journal of Immunology.

T2D is a chronic inflammatory disease in which the body has high levels of glucose in the blood due to the lack of insulin or the body's inability to use insulin efficiently. The incidence of T2D continues to rise at alarming rates in both children and adults in the United States.

Previous research done in mice has shown that T cells play a critical role in the development of insulin resistance in response to a high fat diet, often leading to T2D. Additional findings indicate that T cells exhibit a pro-inflammatory response more often than an anti-inflammatory response.

Working with human T cells, the team observed that in order for T cells to exhibit the pro-inflammatory response, they required constant interaction with monocytes, indicating that monocytes play an indirect role in chronic inflammation and T2D.

While it is not known what the homeostatic balance levels are between pro-inflammatory and anti-inflammatory T cells, this study indicates the need to restore a balance in order to halt chronic inflammation and T2D.

"The true importance of our observations is the indication that altering balance among immune system cells could be a fundamentally novel treatment for T2D-associated inflammation and perhaps insulin resistance," said Nikolajczyk.

###

This research was funded by the National Institutes of Health and the American Diabetes Association.

About Boston University School of Medicine

Originally established in 1848 as the New England Female Medical College, and incorporated into Boston University in 1873, Boston University School of Medicine today is a leading academic medical center with an enrollment of more than 700 medical students and more than 800 masters and PhD students. Its 1,246 full and part-time faculty members generated more than $335 million in funding in the 2009-2010 academic year for research in amyloidosis, arthritis, cardiovascular disease, cancer, infectious disease, pulmonary disease and dermatology among others. The School is affiliated with Boston Medical Center, its principal teaching hospital, the Boston and Bedford Veterans Administration Medical Centers and 16 other regional hospitals as well as the Boston HealthNet.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.